J&J touts new sur­vival da­ta pit­ting lung can­cer com­bo against As­traZeneca's ri­val

John­son & John­son re­leased new da­ta sug­gest­ing its lung can­cer com­bi­na­tion Ry­bre­vant and Laz­cluze beat As­traZeneca’s Tagris­so on over­all sur­vival.

In a Phase 3 tri­al …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER